## **Core Concept**
Bleomycin is a chemotherapeutic agent used in the treatment of various types of cancer. It works by inducing DNA strand breaks, thereby inhibiting DNA synthesis and cell division. However, one of its major side effects is toxicity to certain organs.

## **Why the Correct Answer is Right**
The correct answer, **lungs**, is the primary site of bleomycin toxicity. Bleomycin-induced pulmonary toxicity is a well-known side effect, which can manifest as pneumonitis or pulmonary fibrosis. This occurs because bleomycin generates free radicals that damage lung tissue. The mechanism involves the drug's ability to cleave DNA, leading to cell death in lung cells.

## **Why Each Wrong Option is Incorrect**
- **Option A:** The liver is not the primary site of bleomycin toxicity. While liver function tests may be monitored during chemotherapy, bleomycin's primary toxic effect is not hepatotoxicity.
- **Option B:** The kidneys are also not the primary site of bleomycin toxicity. Although monitoring of renal function is important in patients on chemotherapy, bleomycin's major toxic effect is not nephrotoxicity.
- **Option C:** The bone marrow is a common site of toxicity for many chemotherapeutic agents, leading to myelosuppression. However, bleomycin's dose-limiting toxicity is not myelosuppression but rather pulmonary toxicity.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the pulmonary toxicity of bleomycin is dose-dependent and can be irreversible. Monitoring for signs of pulmonary toxicity, such as cough, dyspnea, and decreased lung function tests, is crucial in patients receiving bleomycin. The use of bleomycin is also limited by its potential to cause pulmonary fibrosis, which can be fatal.

## **Correct Answer:** . lungs